Release Tx to attend 134th SICTIC Investor Day at IMD Lausanne (28 November 2024)
All of us at Release Tx are excited to be participating in the the 134th SICTIC Investor Day at IMD, Lausanne on 28 November 2024, where...
top of page
4 days ago1 min read
Release Tx to attend Lenz & Staehelin Founders’ Evening (20 November 2024)
We’re pleased to announce that Release Therapeutics will be attending Founders’ Evening, organised by Lenz & Staehelin on 20 November at...
7 views0 comments
Nov 71 min read
Release Tx to attend Cell Press Tumor Immunology and Immunotherapy Symposium (11 – 12 November 2024)
We are pleased to announce that Release Tx will participate in the upcoming Cell Press LabLinks Tumor Immunology and Immunotherapy...
7 views0 comments
Oct 171 min read
Meet Release Tx at the ESGCT Congress in Rome (22–25 October 2024)
Release Therapeutics is pleased to announce our participation in the European Society of Gene and Cell Therapy (ESGCT) Congress that will...
10 views0 comments
Sep 251 min read
Meet Release Tx at FutureHealth Lausanne 2024 (1 October 2024)
Release Therapeutics is thrilled to announce our participation in FutureHealth Lausanne 2024, which kicks off at the SwissTech Convention...
22 views0 comments
Aug 62 min read
Release Therapeutics Secures CHF 3.3 Million in Seed Funding
The funding follows the Company’s first preclinical results in metachromatic leukodystrophy and will be invested in studies in non-human...
140 views0 comments
Jul 193 min read
Release Tx Announces Research Collaboration with Paris Brain Institute to Treat Metachromatic Leukodystrophy (MLD) and First Preclinical Results
We are thrilled to announce our strategic collaboration with Paris Brain Institute to explore the potential of our cutting-edge cell...
134 views0 comments
Jun 272 min read
Press Release: Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy
87 views0 comments
Jun 187 min read
Release Therapeutics publishes cutting-edge research in Cell Press
Release Therapeutics publishes cutting-edge research in Cell Press
131 views0 comments
Jun 156 min read
Treating Genetic Disorders of the CNS without Gene Therapy (or what we’ve been up to here at Release Therapeutics)
Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.
147 views0 comments
Jun 141 min read
Meet us online at RESI Europe (18-19 June 2024)
Release Therapeutics is excited to announce our participation in the virtual partnering segment of RESI Europe, Barcelona from June...
5 views0 comments
Jan 131 min read
Meet us at the WORLDSymposium
Release Tx will join the 20th annual WORLDSymposium in San Diego. https://worldsymposia.org/
18 views0 comments
Oct 20, 20231 min read
Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
AACR American Association for Cancer Research Orlando Florida Poster Grogg et al. 2023. iScience. Engineering a versatile and retrievable...
18 views0 comments
Sep 15, 20231 min read
MaxiVAX transitions into Release Tx
We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into...
54 views0 comments
May 31, 20221 min read
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
Molecular Therapy – Methods & Clinical Development Immortalized human myoblast cell lines for the delivery of therapeutic proteins using...
12 views0 comments
Jan 11, 20221 min read
Best Poster Awards 2022: Personalized immunotherapy with encapsulated cell technology
Best Poster Awards 2022 – ESMO conference – Our ECT technology as adjuvant to an au tologous cancer vaccine.
5 views0 comments
Jan 11, 20171 min read
CTI Swiss Medtech Awards
Our ECT technology as adjuvant to an autologous cancer vaccine.
3 views0 comments
bottom of page